SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) witnessed a sharp rebound on Friday, with shares closing at $13.19, up 12.3% from the prior session. The gain adds to a week that saw the stock recover from two consecutive steep declines, ultimately posting a modest 3.4% weekly increase.
The rally comes as the company's estimated equity value has surged by approximately $1.62 billion since May 12, when shares were trading at $5.22. Based on the latest share count from June 2, the total equity value now stands at roughly $2.59 billion, a 167% increase from the $0.97 billion valuation in mid-May.
Notably, the company's disclosed liquidity—comprising $107.1 million in cash as of March 31 plus $28.7 million from warrant exercises in April and May—totals about $135.8 million before second-quarter expenses. This gross liquidity represents only about 5.2% of the current equity value, highlighting the market's focus on future potential rather than current assets.
The primary catalyst driving investor sentiment is the ongoing REGAL Phase 3 trial evaluating galinpepimut-S (GPS) in acute myeloid leukemia patients who are in second complete remission. The trial's primary endpoint is overall survival, with database lock, blinded review, statistical analysis, and unblinding set to commence upon the 80th death event. As of May 12, 78 of the expected 80 deaths had been reported.
CEO Angelos Stergiou described the upcoming results as "an important milestone for the Company." SELLAS has committed to publicly announcing when the 80th event occurs, which will trigger the final analysis process.
Trading volume on Friday reached 11.2 million shares, the highest level of the week, indicating strong investor interest. Analyst coverage remains limited, but those following the stock are bullish. Maxim's Jason McCarthy reiterated a Buy rating with a $30 price target on July 9, while Alliance Global's James Molloy also maintained a Buy and set a $25 target on July 6.
Looking ahead, the REGAL timeline remains event-driven and thus uncertain. An 80th-event notification would signal the start of the lock-and-analysis phase. A separate catalyst is anticipated in the fourth quarter, when SELLAS plans to report top-line data from an 80-patient first-line AML trial of SLS009.
Risks remain, including the possibility that REGAL may fail to meet its survival endpoint or produce inconclusive data. Additionally, SELLAS has access to a $150 million at-the-market (ATM) facility, which, if utilized, could dilute existing shareholders. As of May 12, the company had not drawn on this facility.
Despite Friday's recovery, the valuation gap between the company's market capitalization and its tangible liquidity remains wide. The gross liquidity proxy continues to represent roughly one-twentieth of the estimated equity value, underscoring the speculative nature of the current valuation.
